In phase 2 study of INO-5401 in combination with cemiplimab, Inovio Pharmaceuticals Inc (NASDAQ:INO) achieved success in ensuring the progression-free survival of patients who are diagnosed with GBM (glioblastoma multiforme). The phase 2 study is conducted using INO 9012, and INO 5401 in combination with a PD-1 blocking antibody – Libtayo on fifty-two patients diagnosed […]
Sign Up To Get Our Instant Alerts!
- JPMorgan Bringing Back Employees to Work From Office 433 views
- Apple Employee Claims to Have Been Dismissed After Leading Movement Against Harassment 316 views
- Spotify Records 20% Increase in Paid Subscribers in the Second Quarter 305 views
- Solar Car Company Sono Motors Files For United States IPO 247 views
- Ferari Poaches New CEO From Tech Industry 237 views